Gilead and Goldfinch Bio enter drug development deal

Goldfinch plans to extend the scope of the KGA registry from orphan kidney diseases to include diabetic kidney disease. Credit: Vachagan Malkhasyan from Pixabay.



  • Gilead and Goldfinch Bio enter drug development deal